Skip to content

CareDx CDNA Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Natera, Inc. logo
Natera, Inc.NTRA
NeoGenomics logo
NeoGenomicsNEO
GeneDx Holdings logo
GeneDx HoldingsWGS
Veracyte logo
VeracyteVCYT
Guardant Health logo
Guardant HealthGH

Other financials

Income statement

See full
Revenue$117.7M+39.0%
Operating income$1.2M+109%
Net income$2.8M+127%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$78.5M-12.1%
Total debt$24.5M-19.1%
Total equity$313.5M-17.3%
Total assets$411.1M-16.0%

Cash flow

See full
Operating cash flow$4.3M+116%
CapEx$3.8M+134%
Free cash flow$514.0K+102%

Valuation

See full
Market cap$1.4B+32.2%
Enterprise value$1.35B+34.6%
P/S3.4×+0.3×

Profitability

See full
Gross margin65.5%
Operating margin-3.9%-18.3pp
Net margin-2%-19.9pp
FCF margin-0%0.0pp

Returns & leverage

See full
Return on equity-2.4%-21.9pp
Debt / equity0.1×0.0×
Current ratio3.4×-0.7×

Where this comes from

Reported directly by CareDx in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: CareDx’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about CareDx's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CareDx's common stock, shares authorized (in shares)?
CareDx (CDNA) reported common stock, shares authorized (in shares) of $100M in Q1 2026.
How has CareDx's common stock, shares authorized (in shares) changed year-over-year?
CareDx's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $100M to $100M.
What is the long-term trend for CareDx's common stock, shares authorized (in shares)?
Over 5 years (2020 to 2025), CareDx's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $100M to $100M.